Arabic Arabic English English French French German German
dark

U.S. Commercial Launch of the Matriform Si for Spinal Fusion Procedures: Designed to Enhance New Bone Formation

U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft strip designed and cleared for spinal fusion procedures has been launched. The news was announced today by Xtant Medical Holdings, a technology company focused on surgical solutions for the treatment of spinal disorders.

The Matriform Si Strip is resorbable, osteoconductive, and has a cancellous bone-like structure. It is prepared from Beta-tricalcium phosphate (?-TCP) and porcine collagen for its intended use in filling and bridging degenerative or traumatic bone defects.

“We are excited to launch Matriform Si in the U.S., which expands our biologics portfolio offering and increases our footprint in the U.S. orthopedic Bone Graft Substitute market,” said Kevin Brandt, Chief Commercial Officer of Xtant Medical. “This innovative synthetic is an ultraporous, interconnected structure that is designed to enhance new bone formation and mechanical stability while preventing premature dissolution for spinal fusion procedures. Our team remains committed to advancing our product portfolio, supporting distributors, and providing new tools for surgeons to drive better patient care. Bringing the Matriform Si to market is a testament to our team’s focus and dedication.”

Matriform(R) Si was developed to resemble the composition and porous structure of natural human bone. Comprised of 96% pure phase ?-TCP granules and 4% bioglass, Matriform Si is designed to provide the ideal biomimetic scaffold for spinal fusion procedures. The flexible strip is designed to offer excellent handling and shape memory, ensuring direct contact with the surface of healthy bone.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

4 Midwestern states see rise in positive COVID-19 tests: 4 CDC updates

Next Post

Guardant Health Receives FDA EUA for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test

Related Posts
Total
0
Share